Vanda Pharmaceuticals Inc. is a Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients.
Vanda Pharmaceuticals Inc. (VNDA) had a good day on the market for Monday February 08 as shares jumped 2.97% to close at $15.61. About 347,043 shares traded hands on 3,809 trades for the day, compared with an average daily volume of n/a shares out of a total float of 54.69 million. After opening the trading day at $15.28, shares of Vanda Pharmaceuticals Inc. stayed within a range of $15.72 to $14.99.
With today’s gains, Vanda Pharmaceuticals Inc. now has a market cap of $853.74 million. Shares of Vanda Pharmaceuticals Inc. have been trading within a range of $15.24 and $7.12 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.
Vanda Pharmaceuticals Inc is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.
Vanda Pharmaceuticals Inc. is based out of Washington, DC and has some 284 employees. Its CEO is Mihael Hristos Polymeropoulos.